INDIANAPOLIS - Eli Lilly and Company released new clinical trial results on Nov. 14 for ObesityWeek 2026 in Washington, showing its investigational EloraTZP combination achieved up to 23.3% average weight loss at 48 weeks. Separate Phase 3 data showed Zepbound lowered body mass index by 21.4% in adolescents.
What happened?
In a Phase 2 trial of adults with obesity or overweight and type 2 diabetes, EloraTZP—combining eloralintide and tirzepatide—produced weight loss of up to 54.1 lbs (23.3%) from a 232.4-lb baseline, lowering A1C by up to 2.9%. "EloraTZP delivered weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks from an average baseline of 232.4 lbs in adults with obesity or overweight and type 2 diabetes," Eli Lilly stated in its Nov. 14 release. Up to 60% of participants no longer met obesity BMI criteria, and 77% reached normal blood sugar levels.
Why does it matter?
The results expand obesity care beyond weight reduction into related chronic conditions such as sleep apnea and joint pain. In the Phase 3 SURMOUNT-ADOLESCENTS trial, Zepbound reduced BMI by an average of 21.4% at 72 weeks in patients aged 12 to under 18 years. Meanwhile, investigational triple agonist retatrutide cut sleep-apnea breathing disruptions by up to 36.1 events per hour (60.6%) at 80 weeks in TRIUMPH-1 and lowered knee osteoarthritis pain scores by up to 75.8% in TRIUMPH-4.
What comes next?
Lilly researchers will present full oral session findings for EloraTZP, Zepbound, and retatrutide on Sunday, Nov. 15, between 3:30 p.m. and 6:30 p.m. ET. Reuters noted that complete trial datasets have not yet been published, leaving regulatory timelines dependent on final Phase 3 readouts.
